

Pathophysiological changes in the extracellular matrix but not inflammation were induced by cigarette smoke as early events in fresh human lung tissue

H. Obernolte¹, D. Ritter¹, J. Knebel¹, M. Niehof¹, P. Braubach², D. Jonigk², G. Warnecke², P. Zardo², H.-G. Fieguth³, O. Pfennig³, A. Braun¹, K. Sewald¹



¹ Fraunhofer Institute for Toxicology and Experimental Medicine; ² Medical School Hannover; ^{1,2} Member of the German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH) research network, Member of the Cluster of Excellence Regenerative Biology to Reconstructive Therapy (REBIRTH), Hannover, Germany; ³ KRH clinics, Hannover, Germany

Introduction

Inhalation of cigarette smoke (Cs) is a main reason to develop chronic obstructive pulmonary disease (COPD), characterised by degradation of alveoli and emphysema development, mucus overproduction and inflammation (1). The pathophysiology of COPD is not well understood so the mechanisms that underlie various components of COPD need to be modelled *in vitro*, especially using Cs. In this study, we assessed the pathophysiological effects of Cs and Cs condensate (Csc) on fresh human lung tissue.

Materials and Methods

Human Precision-Cut Lung Slices (PCLS) were exposed to Csc submerged or whole Cs in an Air-Liquid Interface (ALI) using the *in vitro* exposure device P.R.I.T.[®] ExpoCube[®]. Tissue viability and release of proteins were measured and gene expression analysis upon RNA isolation from PCLS was performed.

Results

PCLS exposed to Csc submerge or Cs in ALI culture showed a concentration-dependent increase in cytotoxicity after 24 h. EC₅₀ values were determined using WST-1 assay. EC₅₀ values of 196 µg/mL for Csc and 16 µg particles deposited on human lung tissue for Cs were calculated (Fig. 2).




Fig. 2: Viability of human PCLS after 24 h exposure to increasing concentrations of Csc (A) or Cs (B) was assessed by WST-1 assay. N=4 for Csc, N=3 for Cs, technical duplicates.

Gene expression analysis upon RNA isolated from human PCLS exposed to a non-toxic dose of Csc of literature-based COPD-relevant genes indicate epithelial damage by upregulation of genes involved in tissue injury (MMPs) and metabolic activity (CYPs). Samples exposed to LPS as a control substance did not show an increase in emphysema-associated genes but in genes indicating inflammation (interleukins). (Fig. 3).




Fig. 3: Fold regulation of selected mRNAs in human lung tissue slices treated with LPS or Csc for 24h. The heat map indicates that LPS and Csc stimulation for 24h induces expression of inflammatory and epithelial genes in human PCLS, respectively. RT² Profiler PCR Array (Qiagen). N=4

In detail, fig. 4 presents expression of genes upregulated by Csc (A, B) and genes upregulated by LPS but not regulated by Csc (C-F).

These data can be supported on protein level. Increased production of proteins related to the extracellular matrix (e.g. MMP9, RAGE) were induced and expression in pro-inflammatory cytokines was reduced after Cs exposure in ALI. Supportive results were presented in BAL samples from COPD subjects showing markers of apoptosis (2).



Fig. 1: Experimental setup for submerge exposure to Csc for 24 h (B) and for exposure of lung tissue to cigarette smoke at ALI (A).




Fig. 4: Relative regulation of selected mRNA levels in response to LPS or Csc compared to the respective control groups at 24h. Standard RT² Profiler PCR Array for fibrosis (Qiagen). N=3.




Fig. 5: Production of pro-inflammatory cytokines and ECM proteins in PCLS after Cs exposure were quantified by ELISA. Statistical significance is indicated by *p<0.05, **p<0.01. N=3 for A-C, N=4 for D-F.

Conclusions

These results indicate that early stages of Cs induced lung tissue changes are primarily not provoked by immunological processes but by apoptosis, increased specific metabolic activity and damage of the epithelium.

References

- (1) Shaykhiev, Renat; Crystal, Ronald G. (2014): Annals of the American Thoracic Society 11 Suppl 5, S252-8. DOI: 10.1513/AnnalsATS.201402-049AW.
- (2) Hodge, S.; Hodge, G.; Holmes, M.; Reynolds, P. N. (2005): The European respiratory journal 25 (3), S. 447-454. DOI: 10.1183/09031936.05.00077604.

Contact

Helena Obernolte, Fraunhofer ITEM, Hannover, Germany
helena.obernolte@item.fraunhofer.de, www.item.fraunhofer.de

